NTT
21.5.2020 21:02:11 CEST | Business Wire | Press release
In preparation for the rescheduled 104th Indianapolis 500 presented by Gainbridge, NTT Corporation (NTT) today announced enhancements to Indianapolis Motor Speedway (IMS) that will accelerate smart technologies to improve the INDYCAR fan experience and safety when the Greatest Spectacle in Racing returns Sunday, Aug. 23, 2020.
“We are excited that when fans arrive at IMS for the Indy 500 they will be greeted with an improved, world-class and one-of-a-kind trip to the Racing Capital of the World,” said Mark Miles, Penske Entertainment Corp. President & CEO. “The future of sports will be driven by the ability to use technology to enhance fan experience, safety and convenience. NTT is helping IMS and INDYCAR find new and exciting ways to blend tradition with innovation and ultimately preserve and further The Greatest Spectacle in Racing’s history of discovery and progress.”
NTT will leverage the company’s Accelerate Smart data platform to power a 100-foot wide Media Wall at the base of the landmark Pagoda building, which will provide fans with access to data-driven race insights in real-time. The debut of the highly visible Media Wall will capture fans’ attention with 3D experiences, visualization of 143 data points from every car and multiple live feeds throughout the track. NTT’s Accelerate Smart platform will also use machine learning to indicate where cars should be on the track and predict their next move, while AI will pinpoint the best on-track battles and highlight head-to-head matchups in real-time with pit predictions, top speeds and more.
“NTT’s Accelerate Smart platform is super-charging efforts to significantly enhance the fan-experience at IMS. At this year’s Indy 500, the platform’s statistics and information will power a transformed Pagoda Plaza experience, providing key and engaging competition insights never previously available to in-venue fans in real time,” said Indianapolis Motor Speedway President, J. Douglas Boles. “In addition, NTT will also boost our safety and security grid, contributing to the well-being of spectators and event participants at the world’s largest single-day sporting event.”
At IMS, NTT’s Accelerate Smart solution includes safety and security measures that will offer more effective event security operations and oversight. Data analytics and insights will provide crowd and vehicle congestion detection and alerts that predict rates based on trends at the gates and tunnels. The digital-enabled, enhanced safety and security will establish a model to promote a consistent experience at IMS, as well as all INDYCAR venue events.
“The future of sport means providing fans with digital-first content, better access to technology and leveraging venues, such as IMS, to engage fans through new channels,” said Akira Shimada, Senior Executive Vice President, NTT. “Our Accelerate Smart data platform allows us to digitally transform INDYCAR’S fan engagement to retain its standing as a leader in motorsports, while also creating a safer race day experience.”
Penske and IMS leadership have made connectivity a key theme of investment to allow fans access to as much data and information in real-time as possible. As part of the digital focus, NTT has also evolved the INDYCAR Mobile app powered by NTT DATA to provide fans a second screen to view live in-car camera video during races, track weather forecasts, create and follow fantasy teams, watch on-demand highlights and more.
NTT’s is committed to accelerating the future of smart racing and creating the next generation of INDYCAR fans who want to enjoy the sport through a more digital experience. This is in part why NTT, a global information technology and communications leader, has been the title sponsor of the NTT INDYCAR SERIES since 2019, as well as the Official Technology Partner of INDYCAR, the NTT INDYCAR SERIES, Indianapolis Motor Speedway, Indianapolis 500 and NASCAR’s the Brickyard 400.
About NTT
NTT believes in resolving social issues through our business operations by applying technology for good. We help clients accelerate growth and innovate for current and new business models. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data center and networks all supported by our deep industry expertise and innovation.
As a top 5 global technology and business solutions provider, our diverse teams operate in 88 countries and regions and deliver services to over 190 of them. We serve 85% of Fortune Global 100 companies and thousands of other clients and communities around the world.
For more information on NTT, visit www.global.ntt/
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200521005270/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom